Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06976736 · ClinicalTrials.gov registry record
A Long Term Follow-up Study of TScan TCR-T Products
A clinical trial of AML and MDS, sponsored by TScan Therapeutics.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 2
- Study locations
NCT06976736 is a study of AML and MDS that is actively recruiting participants, run by TScan Therapeutics. The registered enrollment target is 1,000 participants, above the 99-participant average among 29 other AML trials with a reported enrollment target (910% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT06976736, a study of AML and MDS, is actively recruiting participants, sponsored by TScan Therapeutics.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this Long-Term Follow-Up (LTFU) study is to monitor participants who have previously received TSC-100 or TSC-101 TCR-T therapies in the TSCAN-001 study. Participants will be monitored for 15 years from the date of TCR-T cell therapy administration to assess long-term safety and efficacy.
Interventions
- OTHER Observational
Study Locations (2)
California
- City of Hope - Duarte
New York
- Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2025-09-09 |
| Est. Completion | 2040-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06976736
The ClinicalTrials.gov registry entry for NCT06976736 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 99-participant average among 29 other AML trials with a reported enrollment target (910% higher). The listed sponsor is TScan Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with AML appearing as the primary indexed condition, and to 1 intervention - of which Observational is the first listed.
NCT06976736 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, New York.
Frequently Asked Questions
What is clinical trial NCT06976736 about?
NCT06976736 is a clinical study titled "A Long Term Follow-up Study of TScan TCR-T Products". The purpose of this Long-Term Follow-Up (LTFU) study is to monitor participants who have previously received TSC-100 or TSC-101 TCR-T therapies in the TSCAN-001 study. Participants will be monitored for 15 years from the date of TCR-T cell therapy administration to assess long-term safety and effica...
What is the current status of trial NCT06976736?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2025-09-09. Estimated completion is 2040-09.
What conditions does trial NCT06976736 study?
This clinical trial studies the following conditions: AML, MDS, ALL.
What interventions are being tested in trial NCT06976736?
The interventions under investigation include: Observational (OTHER).
Who is sponsoring clinical trial NCT06976736?
This trial is sponsored by TScan Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06976736 being conducted?
This trial has 2 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for AML
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Revumenib in Combination With 7+3 + Midostaurin in AML
RECRUITING · Phase 1
-
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
RECRUITING · Phase 1
-
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
RECRUITING · Phase 1
-
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RECRUITING · Phase 1
-
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RECRUITING
-
Familial Investigations of Childhood Cancer Predisposition
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.